CO2024005252A2 - Dendrones peptídicos y métodos de uso de los mismos - Google Patents

Dendrones peptídicos y métodos de uso de los mismos

Info

Publication number
CO2024005252A2
CO2024005252A2 CONC2024/0005252A CO2024005252A CO2024005252A2 CO 2024005252 A2 CO2024005252 A2 CO 2024005252A2 CO 2024005252 A CO2024005252 A CO 2024005252A CO 2024005252 A2 CO2024005252 A2 CO 2024005252A2
Authority
CO
Colombia
Prior art keywords
dendrons
peptide
methods
therapy
formula
Prior art date
Application number
CONC2024/0005252A
Other languages
English (en)
Inventor
Morgan Audrey Urello
Ronald James Christie
Hannah Vaughan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2024005252A2 publication Critical patent/CO2024005252A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

(I) La memoria descriptiva se refiere a dendrones peptídicos que comprenden uno o más residuos derivados de una lisina modificada de fórmula (I), a sistemas de administración farmacéutica que comprenden estos dendrones peptídicos, a composiciones farmacéuticas que los contienen, y a su uso en terapia.
CONC2024/0005252A 2021-10-08 2024-04-25 Dendrones peptídicos y métodos de uso de los mismos CO2024005252A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163262269P 2021-10-08 2021-10-08
PCT/IB2022/059608 WO2023057975A1 (en) 2021-10-08 2022-10-07 Peptide dendrons and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2024005252A2 true CO2024005252A2 (es) 2024-05-10

Family

ID=83995423

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0005252A CO2024005252A2 (es) 2021-10-08 2024-04-25 Dendrones peptídicos y métodos de uso de los mismos

Country Status (16)

Country Link
EP (1) EP4412662A1 (es)
JP (1) JP2024537869A (es)
KR (1) KR20240082404A (es)
CN (1) CN118119411A (es)
AR (1) AR127281A1 (es)
AU (1) AU2022361764A1 (es)
CA (1) CA3233268A1 (es)
CO (1) CO2024005252A2 (es)
CR (1) CR20240185A (es)
DO (1) DOP2024000066A (es)
EC (1) ECSP24035412A (es)
IL (1) IL311853A (es)
MX (1) MX2024004334A (es)
PE (1) PE20241473A1 (es)
TW (1) TW202342497A (es)
WO (1) WO2023057975A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081979A4 (en) * 2006-08-17 2012-07-18 Univ Utah Res Found DENDRIMERE AND METHOD FOR THE PRODUCTION AND USE THEREOF
US9526693B2 (en) * 2010-03-16 2016-12-27 Sanford-Burnham Medical Research Inslilute Delivery of agents using interfering nanoparticles
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
US9745421B2 (en) * 2013-03-20 2017-08-29 The Regents Of The University Of California Dendronized polymers for nucleic acid delivery
CN114375299A (zh) * 2019-08-07 2022-04-19 伯尔尼大学 用于核酸转染的立体选择性pH响应肽树枝状聚合物
CA3194894A1 (en) * 2020-10-09 2022-04-14 Sumitomo Pharma Co., Ltd. Oligonucleic acid conjugate
CN117915958A (zh) * 2021-04-02 2024-04-19 蒂巴生物技术有限公司 作为在基因递送中的非病毒载体的树枝状结构

Also Published As

Publication number Publication date
AR127281A1 (es) 2024-01-03
MX2024004334A (es) 2024-04-24
ECSP24035412A (es) 2024-06-28
CN118119411A (zh) 2024-05-31
PE20241473A1 (es) 2024-07-17
KR20240082404A (ko) 2024-06-10
CA3233268A1 (en) 2023-04-13
EP4412662A1 (en) 2024-08-14
AU2022361764A1 (en) 2024-05-16
IL311853A (en) 2024-05-01
CR20240185A (es) 2024-06-11
DOP2024000066A (es) 2024-05-31
WO2023057975A1 (en) 2023-04-13
JP2024537869A (ja) 2024-10-16
TW202342497A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
BR112018005746A2 (pt) composições para higiene bucal e métodos de uso.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
BR112022001897A2 (pt) Composições de higiene pessoal
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CO2024005252A2 (es) Dendrones peptídicos y métodos de uso de los mismos
CO2023012342A2 (es) Inhibidores de enzimas
BR112022005958A2 (pt) Composições de higiene bucal e métodos de uso
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112023019917A2 (pt) Uso de uma composição farmacêutica
DOP2021000028A (es) Formulaciones de dendrímeros
UY39187A (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek
BR112018011590A2 (pt) formulação cosmética
CO2022006965A2 (es) Inhibidores de egfr